Even after an additional 12-months follow-up of the IMbrave150 study, atezolizumab plus bevacizumab maintained clinically meaningful survival benefits over sorafenib....
A consensus process initiated by the International Autoimmune Hepatitis Group (IAIHG) proposes the following criteria: Complete biochemical response: normalization of...
The best candidates for nucleos(t)ide analogue withdrawal are virally suppressed, HBeAg-negative, non-cirrhotic patients with low HBsAg levels, particularly Whites with...
The newly developed CRAFITY score, composed of C-reactive protein and alpha-fetoprotein, is associated with survival and radiological response in patients...
A recent meta-analysis indicates that for the treatment of cirrhosis-associated portal vein thrombosis, the bleeding risk is comparable between DOAC...
A recent American population-based study shows that autoimmune hepatitis in pregnancy is associated with significant maternal and perinatal risks such...
A recent meta-analysis shows that non-alcoholic fatty liver disease (NAFLD) is significantly associated with an approx. 1.45-fold increased long-term risk...
Proton-pump inhibitors (PPIs) are currently linked to an unfavorable course of several conditions. In hereditary, HFE-associated hemochromatosis, however, PPI therapy...